← Back to All Filings

Axsome Officer Discloses $34.6M in Stock Sales via 10b5-1 Plan

High SignificanceNovember 5, 2025 at 7:32:47 PM EST

Axsome Therapeutics, Inc.

$AXSM144CIK: 0001579428

Subscribe to track AXSM

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Axsome Officer Discloses $34.6M in Stock Sales via 10b5-1 Plan

Company: Axsome Therapeutics, Inc. (AXSM) Form: 144 | Filed: 2025-11-05 Significance: High

Insider: Herriot Tabuteau Title: Officer | Relationship: Officer

Transaction (Proposed Sale): • Type: Proposed Sale • Shares: 21,775 • Price: ~$135.69 • Value: $2,954,650

Key Insight: This filing is part of a pre-scheduled 10b5-1 selling plan. While this single transaction is small, it reveals a pattern of significant, ongoing selling by a key officer, totaling over $34.6M in the last 90 days.

Market Context: The cumulative sales represent over 0.5% of the company's total shares outstanding. The pre-planned nature mitigates negative sentiment, but the scale of the selling is notable for a $6.8B market cap company.

Comprehensive Analysis

SEC Filing Analysis: Axsome Therapeutics, Inc. (AXSM)

Executive Summary

  • Trading Significance: High
  • Key Takeaway: A key officer at Axsome Therapeutics is engaged in a significant, systematic selling program under a pre-arranged 10b5-1 plan, with total sales exceeding $34 million over the past 90 days.
  • Market Impact: Neutral. The pre-scheduled nature of the sales under a 10b5-1 plan mitigates concerns of trading on new non-public information, but the substantial and consistent volume of sales from a top executive warrants attention.

Company Information

FieldValue
CompanyAxsome Therapeutics, Inc.
Ticker SymbolAXSM
CIK0001579428
IndustryPharmaceutical Preparations

Insider Information

FieldValue
NameHerriot Tabuteau
CIK0001219927
Title/PositionOfficer
RelationshipOfficer

Transaction Details

FieldValue
Form Type144 (Notice of Proposed Sale)
Transaction Date2025-11-05 (Approximate)
Transaction CodeS (Sale)
Security TypeCommon Stock
Shares Involved21,775
Price Per Share$135.69 (approx.)
Total Value$2,954,649.75
Shares Owned AfterNot specified
Ownership TypeNot specified

Financial Impact Assessment

Transaction Materiality (Proposed Sale)

MetricValue
Transaction Value$2.95 million
% of Market Cap0.043%
Shares Transacted21,775
% of Shares Outstanding0.044%
Materiality AssessmentLow (in isolation)

Impact Evaluation

  • Cumulative Selling Analysis: While the single proposed sale is minor, the filing discloses a pattern of significant selling. Including this transaction, the insider has sold or proposed to sell approximately 272,203 shares for a total value of ~$34.62 million in the past 90 days.
  • Cumulative Materiality: The total shares sold (272,203) represent 0.55% of shares outstanding, and the total value ($34.62M) represents 0.51% of the company's market cap. This cumulative activity crosses the threshold for High Significance.
  • Market Cap Context: For a mid-cap company with a $6.83 billion market capitalization, a $34.6 million divestment by a key officer is a substantial event, even when executed through a planned selling program.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The sales are executed under a Rule 10b5-1 plan adopted on June 13, 2025. This indicates the sales are pre-scheduled for liquidity or diversification purposes and not based on immediate, adverse company information. However, the persistent supply of shares from an insider can create a headwind for the stock price.

Volume & Sentiment

  • Expected Volume Impact: The consistent selling may contribute to daily trading volume but is unlikely to cause dramatic single-day spikes, as the sales appear to be spread out.
  • Sentiment Indicator: Neutral. The market generally views 10b5-1 plan sales as less informative than spontaneous sales. The high cumulative value is a bearish data point, balanced by the planned nature of the trades.

Investment Insights

Positive Market Indicators

  • No positive indicators can be derived from this insider selling filing.

Risk Factors

  • Insider Selling Pressure: A consistent, high-volume outflow of shares from a key executive, even if planned, can signal that the insider sees limited near-term upside or is de-risking their position.
  • Perception: Large-scale selling can be perceived negatively by the market, regardless of the reason, potentially weighing on investor sentiment.

Key Takeaways

  1. An officer is systematically selling a large block of stock, totaling over 0.5% of the company's shares outstanding over a 90-day period.
  2. The sales are part of a pre-disclosed 10b5-1 plan, which reduces the likelihood that they are based on negative inside information.
  3. The total value of the sales is significant relative to the company's market capitalization, making this a highly notable pattern of insider activity.

Additional Context

Special Circumstances

  • The filing explicitly states, "The sales of shares set forth herein are made in connection with a selling plan dated 6/13/2025, that is intended to comply with Rule 10b5-1(c)." This context is crucial for interpreting the insider's actions.
Topics:#SECFiling#InsiderSelling#AXSM#Form144#HighSignificance#StockAlert#10b51#AxsomeTherapeutics#Investing#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.